Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Gains from Sales and Divestitures: 2016-2023

Historic Gains from Sales and Divestitures for Solid Biosciences (SLDB) over the last 6 years, with Dec 2023 value amounting to $183,951.

  • Solid Biosciences' Gains from Sales and Divestitures was N/A to $237,315 in Q3 2024 from the same period last year, while for Sep 2024 it was $237,315, marking a year-over-year change of. This contributed to the annual value of $183,951 for FY2023, which is N/A change from last year.
  • Latest data reveals that Solid Biosciences reported Gains from Sales and Divestitures of $183,951 as of FY2023, which was down 56.12% from $419,193 recorded in FY2021.
  • Solid Biosciences' 5-year Gains from Sales and Divestitures high stood at $419,193 for FY2021, and its period low was $183,951 during FY2023.
  • Moreover, its 2-year median value for Gains from Sales and Divestitures was $301,572 (2021), whereas its average is $301,572.
  • Data for Solid Biosciences' Gains from Sales and Divestitures shows a peak YoY increased of 20.55% (in 2020) over the last 5 years.
  • Over the past 4 years, Solid Biosciences' Gains from Sales and Divestitures (Yearly) stood at $338,198 in 2019, then rose by 20.55% to $407,700 in 2020, then rose by 2.82% to $419,193 in 2021, then reached $183,951 in 2023.